RTH Foundation Knowledge Base Article

Why and how did BCM become the emerging leader in human organ tissue Regenerative and Replacement Healing

Relationships: All of the human organ tissue regenerative replacement products and procedures delivered by the Right To Heal Foundation ("RTH Foundation") are provided to RTH Foundation by BCM Industries (BCM). The reason RTH Foundation only utilizes BCM produced healing products is well documented in the following presentation of facts and discussion addressing why and how BCM has emerged as the leader in reliable, repeatable, successful delivery of regenerative replacement organ tissues in humans.

Facts: For at least the prior twenty years, thousands of researchers, scientists, engineers, scholars and professionals have tried and failed to achieve reliable, repeatable, successful delivery of regenerative replacement organ tissues in humans.

The BCM Industries Team has overcome all obstacles and is proceeding to commence delivery of the initial set of regenerative replacement human organ tissues for the healing of Liver, Kidney, Lungs, Skin and Pancreas (Beta Tissue to address Type I Diabetes). BCM is also proceeding to address more human organs and diseases solutions using human regenerative replacement products.

Questions:

[1] Why and how is BCM succeeding; when others have failed?

[2] What unique technologies, processes, procedures and operational infrastructures does BCM utilize to deliver this emerging high level of repeatable success?

[3] BCM is currently focused upon five initial organ healing products (Skin, Liver, Kidney, Lung and Pancreas/Beta Tissues); are there more human organs, body parts and diseases that BCM can address utilizing these unique technologies, processes and procedures?

Answers:

[1] and [2] There are many reasons and factors why BCM is taking emerging leadership in regenerative replacement of organ tissues in humans.

The following Table lists sixteen (16) leading reasons and factors. The list is followed by a brief introduction to each item. The Table is not a complete list. Some items have been excluded due to their high classification as BCM proprietary technologies.

[3] BCM has scheduled and is commencing development efforts to address many more human organs, body parts and disease focused regenerative replacement healing products. The results and production schedule details of these activities will be disclosed at a future date.

List of Reasons and Factors

Addressing

BCM Industries Success and Emerging Leadership

Unwavering and Unstoppable Team Commitment to Succeed

Utilization of Archival Knowledge Based Solutions

Replacement Cell Implanted Organ Operating Knowledge

Patient-Organ-Procedure Specific Tissue Production Processes

Continuing Creation of New Technologies, Processes and Procedures

Specialized Healing Structured Matrix Platform Technologies

Utilization of Patient Donated Cell Regeneration Technologies

Multiple Technologies and Sciences Experienced Development Team

Organ and Process Controlled Tissue Creation and Delivery Structure

Application of Proprietary PASS Technologies

Creation of the Ultra Purest Produced Cell Structure Collagen

Fully Controlled and Regulated Source Materials Production Process

Complete Quarantine Based Animal Quality Control and Rejection Process

Use of Proprietary Packaging and Shelf Life Technologies

Implementation of Highest Level of Quality and Compliance Adherence

Availability of Global Tissue Replacement Healing Services

Introduction to BCM Success - Reasons and Factors

1] Unwavering and Unstoppable Team Commitment to Succeed

With specific intention, BCM has assembled and united into a core research, development and production process group, the most dedicated and powerful team of human tissue regeneration and replacement personnel anywhere. This Team has over the last few years continually demonstrated complete dedication to the mission of moving from research to solid reliable, repeatable, successful delivery of regenerative replacement organ tissues in humans.

The BCM Team has an unwavering and unstoppable commitment to complete this mission. To date, the Team has overcome all obstacles. They foresee future issues and technology challenges but are confident that all these issues can be addressed with the skills, technologies, processes and procedures already within the BCM asset portfolio.

2] Utilization of Archival Knowledge Based Solutions

For at least the prior twenty years thousands of researchers, scientists, engineers, scholars and professionals have been in pursuit of the solution to the challenge of healing humans of injuries, failing and diseased organs, and other health issues through the use of new tissue regeneration and replacement.

Much progress occurred and continues; however, the ultimate goal of creating reliable, repeatable, successful delivery of regenerative replacement organ tissues in humans has evaded discovery. The period of searching for a solution is now over. The BCM Team has solved the remaining outstanding mysteries, and created the needed technologies, processes and procedures to deliver this long and hard sought-after solution.

To emerge as a new leader in regenerative and replacement of human tissue healing, the BCM Team studied and analyzed nearly all the efforts of the past. They studied: What worked and what did not; What worked sometimes and failed other times; Why and How these process and procedures might be modified, amended, re-designed, re-cast, combined, de-coupled, phased and re-engineered to be a successful solution.

This was a very tedious and often highly frustrating endeavor that had to be carefully performed and successfully completed. It was from these foundational investigative processes and analysis the ultimate final BCM technologies, processes and procedures evolved.

3] Replacement Cell Implanted Organ Operating Knowledge

This is a BCM proprietary process that fully embeds the initial core set of patient donated organ cells with the full knowledge as to the roles, tasks and functions these core cells are to perform within the “to be grown” human organ segment of the replacement tissues. This unique pre-programmed process and technology assures nearly instant organ functionality of the new replacement tissues. This rapid cell to

organ function adaptation, within the healing organ, means a much higher rate of organ acceptance of the replacement tissues and much quicker organ healing and recovery in the damaged cell replacement process.

These tasks and processes utilize two unique BCM trademarked properties: OKR Cells™ - OKR means “Organ Knowledgeable Replacement;” and ROLEspecs™ - Role means the “Human Cell has been informed and knowns the Function or Role it is to play in the operation of a specific human organ.”

4] Patient-Organ-Procedure Specific Tissue Production Processes

This BCM technology and associated processes and procedures are very critical to the ultimate healing solution. From the injured or diseased patient, a few good organ cells are taken. They become the core for a complex process of growing a band new highly healthy, patient customized, organ knowledgeable, replacement designed organ tissue. This highly customized, patient and organ specific, newly grown PCH Unit™ is then placed into the patient’s injured or diseased organ. The result is the new PCH Unit™ replaces the old, injured, deceased or failing cells with new very healthy and vibrant tissues.

These tasks and processes utilize a unique BCM trademarked property: PCH Unit™ - PCH means “Patient Customized Healing.”

5] Continuing Creation of New Technologies, Processes and Procedures

Although the BCM Team has recorded great accomplishments, there remains many challenges ahead. They include, but are not limited to, developing the exact processes and procedures to: (a) address all of the remaining soft tissue organs in the human body; (b) address all of the cartilage structures and parts in the human body; (c) address many of the diseases and syndromes that impact the human body and mind; (d) address all of these issues in less that earth gravity which means addresses space travel and space residency healing issues.

To delivery BCM healing to these four categories, (a) to (d), requires the BCM Team to continue to adapt the existing technologies, processes and procedures to these additional applications. It also means that new enhanced, adjusted, modified and re-engineered solutions will be required. This adaption and creation process is underway and will continue.

6] Specialized Healing Structured Matrix Platform Technologies

This technology is a BCM proprietary platform design and manufacturing methodology that allows BCM to mold, tailor and transform a unique technology platform source material to address both patient and organ specific tissue regeneration and replacement needs tailored to a specific patient. It is created to fill the void or voids which will result from the injury or disease cell removal surgery.

As a customized HSM Platform™ each BCM designed and created regenerative product delivers a physically solid, void filling, replacement tissue structure. A product

that when inserted into the patient's organ void area, provides rapid cell to organ function adaptation. That means a much higher rate of organ acceptance of the replacement part and much quicker healing and damaged cell replacement recovery process within the voided area.

These tasks and processes utilize a unique BCM trademarked property: HSM Platform™ - HSM means "Healing Structured Matrix." It is an integral part of the PDcell™ process and associated technologies.

7] Utilization of Patient Donated Cell Regeneration Technologies

These products and procedures are based upon a proprietary BCM designed human patient donor-cell based, ROLEspecs™**,** growth technology. BCM has developed a manufacturing methodology that allows this unique technology platform to be transformed and tailored to address both the patient and organ specific tissue regeneration and replacement needs of a specific patient.

BCM is also able to mold these core platforms into organ application specific and patient specific, manufacturing systems. The result is that BCM now has the skills, assets, technology and professional talent to address human organ healing by functional cell defined tasks and also by duty delegations upon the organ cells.

This new technology results in BCM acquiring the power to create fully functional replacement and regenerative organ specific tissues for many types of human soft tissue organs. Currently, BCM is scheduled to address the replacement and regenerative healing of these human organs: Skin; Liver; Lungs; Kidneys; Pancreas Beta Tissue.

The tasks and processes utilize a unique BCM trademarked property: PDcell™ - PD means "Patient Donated." It is a BCM trademark and brand for a continually growing family of highly effective BCM proprietary healing products.

8] Multiple Technologies and Sciences Experienced Development Team

The accomplishments by the BCM Team would not have been possible without the jointing together of many categories and disciplines of science, medicine, engineering, physics, manufacturing, production processing, ranching, pathology, animal genealogy, and many more trades and skill sets. It clearly has been a multiple, cross blending, of all types of skill sets, experiences and individual insight and wisdom all focused applications to address the need for a viable solution.

The created results, regenerative organ tissue replacement healing, is solid proof that BCM was able to entice and blend together into a unified Team the right individuals with the needed skills, wisdom and commitment to succeed.

9] Organ and Process Controlled Tissue Creation and Delivery Structure

To succeed in achieving reliable, repeatable, successful delivery of regenerative replacement of organ tissues in humans, it was necessary to design a manufacturing

program and standard production process that would consistently deliver a medical grade cell growth scaffold structure.

The BCM Team addressed this need with a highly intricate, cross-laced, 3D-interwoven, BCM proprietary scaffold matrix configurations and cell growth platforms . This SCAFmax™ design, with slight application modifications, is used in all the customized growth of regenerative and replacement BCM proprietary healing products lines and custom orders.

These tasks and processes utilize a unique BCM trademarked property: SCAFmax™ - SCAF means a medical grade cell growth scaffold structure.

10] Application of Proprietary PASS Technologies

This BCM unique technology, PASSpower™, is based upon the unification of a few highly effective pathogen collection and killing devices. These devices become elements in a unified application dependent system configuration. Each is designed specifically to accomplish the avoidance and the eradication of possible pathogens that may attempt to enter the BCM source material harvesting and the product manufacturing and production facilities.

This new PASS technology is a unique BCM proprietary combination of equipment, tooling, systems, procedures and policies that have been designed and are fully utilized to effectively address and assure that all BCM regenerative medicine products have the highest purity and safety. The sole purpose of PASSpower™ is to further enhance the purity of all ASM (Animal Sourced Materials) and XM (Xenotransplantation) produced materials utilized in all BCM products and activities.

These tasks and processes utilize a unique BCM trademarked property: PASSpower™ - PASS stands for “Pathogen Avoidance and Suppression Systems.”

11] Creation of the Ultra Purest Produced Cell Structure Collagen

The BCM creation and production of this ultra-pure medical source material is a complex and intricate process. It begins with specialized, and exclusively sourced, BCM administered closed herds that have been raised, harvested and processed in the USA with traceability for at least two generations. These resulting materials successfully meet the US FDA recommended Guidelines as to Pedigree and Handling procedures for materials to be used in medical devices.

The process assures no growth stimulating hormones or GMO products are used in the birthing and rising of the herd. The herds are not exposed to potential carriers of diseases or parasites from outside the herd. Only approved and necessary insecticides, pesticides and antibiotics are used.

All processing and harvesting is done under Standard Operating Procedures and are in cGMP (“current good manufacturing practice”) compliance. These operating controls, procedures and qualified process’ enable BCM to provide the highest quality and purity

materials to all BCM regenerative medicine products. The BCM farms and harvesting facilities are registered with the FDA.

These tasks and processes utilize a unique BCM trademarked property: ULTRApur™ - ULTRA means the “Highest Quality Obtainable.” It is an exclusive BCM proprietary source of materials utilized in all BCM produced regenerative medicine products.

12] Fully Controlled and Regulated Source Materials Production Process

To assure and control product quality, BCM controls and administers the complete process from the very start to the end delivery of each delivered BCM product. Because the process sources materials are ASM (animal sourced materials), BCM has developed and operates quality controls starting at pre-insemination of calf conception. This quality control process is applied during the 6 to 30-month period of growth that occurs on range lands.

To assure ASM monitoring and quality control during this period, BCM has developed a special technology. This ROAMtag™ technology includes a BCM proprietary long-range wireless animal monitoring and control system. It utilizes unique design features and customized technologies to monitor health status, safety, location and other data. It assures BCM administered herds have full quality control while assuring unimpeded space for natural grazing and roaming activities.

These tasks and processes utilize a unique BCM trademarked property: ROAMtag™ - ROAM means “to allow for freedom of movement.”

13] Complete Quarantine Based Animal Quality Control and Rejection Processing

As an element of the complete start to finish quality control, BCM controls and administers a through and detailed animal quarantine monitoring, testing, analysis and pre-proceeding approval and clearance process. QuaraPUR is a BCM proprietary set of processes and procedures utilized to evaluate and re-confirm the health, purity and approved status of a BCM sourced animal prior to harvesting. This process is applied to every candidate animal for harvest. It occurs over an extended 30 day or more period of time. It includes specialized testing, physical and automated evaluations and detailed monitoring activities.

These tasks and processes utilize a unique BCM trademarked property: QuaraPUR™ - Quara means to “Quarantine.”

14] Use of Proprietary Packaging and Shelf Life Technologies

BCM has addressed the need to assure quality is maintained during BCM product deliveries around the world; and also to address new packaging technologies to support the future markets of: (a) Space travel and residency, and (b) the long-term storage in support of emergency preparedness healing product’s needs.

CORApac™ is a BCM proprietary set of process, procedures and packaging that delivers extended shelf life storage and transport of human tissue and organ growth-sourcing materials. The process and associated technologies are configured to be universally available for both terrestrial and space applications.

These tasks and processes utilize a unique BCM trademarked property: CORApac™ - CORA means to “Consolidate and Contain.”

15] Implementation of Highest Level of Quality and Compliance Adherence

BCM processes and procedures, addressing regulatory compliance and quality control systems, meet and exceed all mandated and relevant requirements and/or recommendations of the US FDA, USDA, ASTM and ISO. All BCM sourced animals carry complete traceability from source through processing and are totally BSE free.

BCM will be one of the first companies to register with the US FDA as a source of closed herd material sourced from the USA. Plus, all animals will be US FDA-Registered with Document Master File (“DMF”) number and fully closed herd-compliant.

US FDA closed herd Guidance Document:

> “Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Transplantation Products in Humans” Guidance for Industry for enhanced traceability, December 2016

All BCM products are produced as Medical/Pharmaceutical grade and all ASM extracted materials can be traced to: Pedigree for 2 generations (parents and grandparents) and to a specific sourced animal. Quality systems to be registered with the US FDA (ISO 22442 pending). Food and water consumption is from approved sources only. No animal by-products or GMO’s are ever used in the feeding or processing of BCM sourced animals.

16] Availability of Global Tissue Replacement Healing Services

The timely and reliable, repeatable, successful delivery of regenerative replacement of organ tissues in humans is dependent upon not only the technologies, processes and procedures; but also the regulatory compliance and approvals by country and agency authorities to delivery these human replacement organ tissues to those in need of healing.

The BCM process to address this last and final phase of the organ healing procedure is based upon integration of three mature and existing global focused medical delivery systems. These systems include: (a) countries and regulatory authorities that review and approval the healthcare processes that impact humans; (b) the hospitals and healthcare facilities that are currently, or desire to, participate in regenerative replacement organ tissue healing deliveries and (c) those agencies and travel entities who participate in medical tourism. A BCM Group member, the Right To Heal Foundation, is the prime administrator and business operator that addresses these tasks and activities.

This final phase of BCM activities is not initially scheduled for implementation in the US or the EU. Initially, all BCM delivered healing will be in a selective number of countries that approve of specific BCM healing processes and procedures. Within these selective countries, one or more hospitals and surgeons will participate in the actual organ tissue delivery to the patient.

Those patients, who are not local residents within country that is approved for BCM product delivery, will be required to travel to that approved county and the assigned hospital to perform the patient's organ tissue delivery procedure. These out-of-country patients will commonly travel as Medial Tourist. Medical Tourism is a well-established and growth industry, which is prepared, though the services of the RTH Foundation to fully support this BCM human organ tissue healing program.



To assist in your consideration of any potential business or financial relationship with the Company, BCM is prepared to arrange for your attendance at a private, invitation only, Regenerative Medicine Project presentation and a live organ growth demonstration.

Should this private presentation of BCM Regenerative Medicine be of interest, please use the contact form on this website to request a showing and/or further details.